Immunovant
IPOEnabling normal lives with autoimmune disease
Public · New York, United States · Founded 2018 · $585.0M raised
- Headquarters
- New York, New York
- Employees
- 51–200
- Founded
- 2018
- Business Model
- B2B
- Website
- immunovant.com
- Total Funding
- $585.0M
- Last Round
- $35.0M AngelOct 2019
- Rounds
- 2
- Type
- Public
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
About
Immunovant is a clinical-stage immunology company developing FcRn inhibitor therapies to reduce harmful IgG autoantibodies in autoimmune disease. Its two investigational antibodies, IMVT-1402 and batoclimab, target FcRn as subcutaneous injections with tailored dosing across indications including Graves' disease, myasthenia gravis, and other IgG-mediated conditions.
Summary
Immunovant is a Biotech company based in New York, United States, founded in 2018. It has raised $585.0M in total across 2 rounds, most recently a $35.0M Angel round in Oct 2019.
Tech & App Stack
6 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding & Exit History
Apr 2020
Sign up to see all 3 events
Funding: Angel. Amounts, valuations, and investors where available.
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/immunovant"><img src="https://indexed.vc/api/badge/company/immunovant" alt="Immunovant on Indexed.vc" width="260" height="76" /></a>